Compare RVPH & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | KRMD |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 186.3M |
| IPO Year | N/A | N/A |
| Metric | RVPH | KRMD |
|---|---|---|
| Price | $0.67 | $5.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.33 | ★ $4.83 |
| AVG Volume (30 Days) | ★ 4.4M | 198.2K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $39,070,637.00 |
| Revenue This Year | N/A | $23.36 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.12 |
| 52 Week Low | $0.25 | $1.86 |
| 52 Week High | $2.95 | $6.11 |
| Indicator | RVPH | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 69.43 |
| Support Level | $0.60 | $5.52 |
| Resistance Level | $0.77 | $6.11 |
| Average True Range (ATR) | 0.05 | 0.41 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 61.01 | 76.92 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).